Table 2. Evaluated target agent for hyponatremia and their mechanism of action.

DRUG	MECHANISM OF ACTION
AFATINIB	Irreversible covalent inhibitor of the receptor tyrosine kinases EGFR and erbB-2 (HER2)
BRIVANIB	VEGFR2 inhibitor
CETUXIMAB	Chimeric (mouse/human) monoclonal antibody inhibiting EGFR
GEFITINIB	Elective inhibitor of EGFR tyrosine kinase domain
LINIFANIB	Multi-targeted receptor inhibitor of VEGFR, PDGFR and CSF-1R
PAZOPANIB	Selective multi-targeted receptor tyrosine kinase inhibitor (c-KIT, FGFR, PDGFR and VEGFR)
SORAFENIB	Small multikinase inhibitor (VEGFR, PDGFR and Raf family kinases)
VORINOSTAT	HD inhibitor

Legend. EGFR: Epidermal Growth Factor Receptor, VEGFR: Vascular Endothelial Growth Factor Receptor, PDGFR: platelet-derived growth factor receptor, CSF-1R: colony stimulating factor 1 receptor, FGFR: fibroblastic growth factor receptor, HDI: Histone Deacetylase inhibitor.